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Abstract
Background: Epidemiological studies indicate that gene-environment interactions play a role in atopic 
dermatitis. 
Objective: To review the evidence for gene-environment interactions in atopic dermatitis aetiology, 
focusing on FLG loss-of-function mutations. 
Methods: Systematic search from inception to September 2018 in EMBASE, MEDLINE and BIOSIS. Search 
terms included all synonyms for atopic dermatitis (AD) and filaggrin/FLG; any genetic or epidemiological 
study design using any statistical methods were included. Quality assessment using criteria modified from 
guidance - ROBINS-I and Human Genome Epidemiology Network (HuGENET)- for non-randomised and 
genetic studies was completed, including consideration of power. Heterogeneity of study design and 
analyses precluded the use of meta-analysis.
Results: Of 1,817 papers identified, 12 fulfilled the inclusion criteria required and performed formal 
interaction testing. There was some evidence for FLG-environment interactions in six of the studies (P 
value for interaction ≤0.05) including early-life cat ownership, older siblings, water hardness, phthalate 
exposure, higher urinary phthalate metabolite levels (which all increased AD risk additional to FLG null 
genotype) and prolonged breastfeeding (which decreased AD risk in the context of FLG null genotype). 
Major limitations of published studies were low numbers of individuals with AD and FLG loss-of-function 
mutations and exposure to specific environmental factors (n=5 to 94), and variation in exposure 
definitions. 
Conclusions and relevance: Evidence on FLG-environment interactions in atopic dermatitis aetiology is 
limited. However, many of the studies lacked large enough sample sizes to fully assess these interactions. 
Further research is needed with larger sample sizes and clearly defined exposure assessment. 
Review registration: PROSPERO CRD42017057818
WHAT’S KNOWN STATEMENT
 Gene-environment interactions are considered important in the aetiology of atopic dermatitis.
 Loss of function mutations in the gene coding are the most consistently reported genetic variants 
for atopic dermatitis.
 Studies have reported evidence for gene-environment interaction involving filaggrin and a range 
of different environmental exposures.A
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WHAT’S NEW STATEMENT
 There is some evidence for FLG-environment interactions in the aetiology of atopic dermatitis, 
however the evidence is limited.
 Studies lack large enough sample sizes to achieve adequate power in order to fully assess these 
interactions.
CLINICAL IMPLICATIONS 
Understanding the role of FLG-environment interactions in the aetiology of atopic dermatitis would be 
helpful to tailor preventative strategies, but published evidence is currently lacking. 
KEY WORDS 
Atopic dermatitis, atopic eczema, filaggrin, FLG, exposure, gene-environment interaction.
ABBREVIATIONS 
FLG  Gene encoding filaggrin
GEI Gene-Environment Interaction
HR Hazard Ratio
PROSPERO Prospective Register of Systematic Reviews
PRISMA Preferred Reporting Items for Systematic Review and Meta-Analysis 
ORs Odds Ratios
CI Confidence Interval
PINT P value for the interaction
MEP Monoethyl phthalate
MBP Monobutyl phthalate
MBzP Monobenzyl pthathlate
5OHMEHP Mono(2-ethyl-5-hydroxyhexyl)phthalateA
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Introduction 
Atopic dermatitis (AD), also known as eczema or atopic eczema, is a complex, multifactorial often 
debilitating disease.1  The prevalence of AD has risen rapidly, suggesting that environmental factors might 
be responsible for such changes.2 It is estimated that up to 20% of children and 3% of adults suffer from 
AD in high income countries.3 It is crucial to better understand the aetiology of AD to discover ways to 
reduce the personal and public health burden.
Considerable phenotypic heterogeneity, evidence for multiple genetic risk mechanisms4 and incomplete 
penetrance have led to complexities understanding the genetic basis of AD.5 There have been 31 risk loci 
identified for AD to date.4 Loss-of-function mutations in the gene encoding filaggrin (FLG) are the 
strongest and most significantly associated genetic variants for AD.6
Profilaggrin is an insoluble protein found in the outer epidermis; monomeric filaggrin has multiple 
functions including aggregation of keratin filaments.7 FLG is essential for normal epidermal barrier 
function and formation,8 contributing to the skin water-holding capacity and pH balance.9 The two most 
prevalent loss-of-function mutations in FLG in white European populations are R510X and 2282del4, 
present in approximately 9% of healthy people in northern European populations; these are strongly 
associated with AD risk, particularly early onset and severe disease.6 Other, less prevalent loss-of-function 
mutations in FLG have been identified.10-12 Despite increasing understanding of the importance of genetic 
factors, the rising AD prevalence has been too substantial and rapid to be explained purely by genetic A
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factors.13 Environmental factors have been implicated in the rising AD prevalence; exposure to such 
factors in utero or later life may play a role in AD aetiology.14 
Gene-environment interaction (GEI) may be defined as occurring when individuals with different 
genotypes respond to an environmental exposure in different ways; this interaction contributes to many 
common phenotypes and complex genetic traits. There is evidence that GEI plays a role in atopic diseases, 
such as asthma, in which genotype interacts with environmental factors, including maternal smoking and 
house dust mite.15,16 A recent review on allergic diseases highlighted that several studies exploring GEI in 
AD exist, yet findings have not been synthesised (e.g. in a systematic review).17 Our objective was to 
systematically review the evidence for GEI in AD, focusing on interactions with FLG-null genotype because 
this is the strongest and most widely replicated AD genetic risk factor, and because the role of filaggrin in 
skin barrier function provides a priori support for a hypothetical GEI effect.
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Methods
This systematic review was prospectively registered (PROSPERO ID CRD42017057818)18. A detailed 
electronic search of MEDLINE and EMBASE via Ovid and BIOSIS via Web of Science was undertaken from 
inception of each database to September 2018 identifying manuscripts in any language. To define AD, the 
search terms ‘atopic dermatitis’, ‘atopic eczema’ and ‘eczema’ were used, and to define FLG mutations, 
filaggrin, FLG, possible mis-spellings and previously reported FLG mutation names were included in the 
strategy (Supplementary material methods 1). We focussed on incident AD cases, including studies 
looking at interactions for AD development rather than interactions for established AD. To avoid a priori 
defining an exhaustive list of environmental factors, the inclusion of any environmental factor was 
assessed during the title and abstract screening. We defined environmental exposures as proposed by 
Rothman.19 The primary outcome measure was evidence of a statistically significant (defined as p<0.05) 
FLG-environment interaction in the aetiology of AD and the secondary outcome was the strength of the 
association of the interaction  (evidence of a dose response relationship) and AD severity. For details of 
abstract screening, inclusion and exclusion criteria and data extraction, see Supplementary material 
methods 2 and Supplementary table 1. 
Quality and bias assessment was performed using criteria modified from guidance for non-randomised 
studies to determine quality of studies, ROBINS-I: to assess risk of bias in non-randomised studies of 
interventions, and HuGENet for genetic studies, including assessing if confounders were considered.20,21 
These two tools were combined to determine bias in genetic and environmental studies, as neither tool 
was designed for GEI studies.
Post hoc sample size calculations were undertaken to estimate the sample size required to detect a GEI 
effect varying between 1.2 and 26 in a case-control/cohort study for a binary SNP and binary exposure 
under a series of assumptions for model parameters (Supplementary table 4), using R 3.5.0 (R package 
powerGWASinteraction).
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Results
The search identified 1817 papers of possible relevance (Figure 1); 12 met our inclusion criteria 
(Supplementary Table 1). Papers tested various environmental exposures (Table 1).
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Table 1: Environmental exposures assessed in included studies
Environmental exposures assessed in one 
paper*
Environmental exposures assessed in two or more 
papers *
Older siblings and day-care attendance30, Sex24, 
Maternal parity24, Maternal AD24, Maternal 
smoking24, Environmental tobacco smoke 
exposure in early life24, Birth-year31, Serum 
vitamin D levels32, Maternal IgE sensitization33
Early life cat exposure22,23, Breastfeeding24,25, 
Phthalate exposure in urine metabolites and 
household dust 26,27, Water hardness28,29
*Environmental exposures where significant interactions with FLG were reported (P<0.05) 
Study designs were cohort (10), case-control (1) and a family-based study (1) (Supplementary Table 3). 
Study populations ranged from 296 to 5188 individuals and participant ages were from one month to 69 
years. The number of participants in each study with FLG loss-of-function mutations ranged from 27 
(9.1%) to 459 (10.2%). The AD definition and method of ascertainment varied between studies 
(supplementary table 2).34-36 None of the included studies investigated the strength of interaction or AD 
severity. 
Out of 12 publications, including 15 studies (Supplementary Table 2), six studies showed evidence for GEI 
(P <0.05) (Table 1). Most used regression models to calculate P values and some presented hazard ratios. 
Heterogeneity in study design and exposures precluded formal meta-analysis.
Cat exposure
Two studies assessed the FLG*cat interaction22,23. Bisgaard et al. tested for an interaction in the 
Copenhagen Prospective study on Asthma in Childhood (COPSAC) (n=379) and reported an increased risk 
related to cat exposure at birth amongst children aged 0-5 years with FLG null mutation (HR=11.11, 95% 
CI 3.79-32.60, Pinteraction = 0.0008); findings were replicated in the Manchester Asthma and Allergy Study 
(MAAS)(n=503), with an increased risk due to interaction of cat exposure at birth and FLG null genotype 
(HR=3.82, 95% CI:1.35-10.81, Pinteraction=0.011). Schuttelaar et al (n=934) reported no overall interaction 
(P=0.85) between FLG null genotype (one/two FLG loss-of-function mutations) and cat exposure at home 
(OR with FLG loss-of-function mutation(s) and cat exposure=1.9; OR for FLG wild-type individuals and cat 
exposure=2.1). However, Schuttelaar et al. reported an interaction when examining the 2282del4 A
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mutation only (P=0.003), with a stronger effect in children aged 0-8 years with a cat at home (OR=6.0, 
95% CI:3.2-11.3) compared to those without(OR=2.2, 95% CI:1.4-3.7).23All those with 2282del4 mutations 
were heterozygous.23 As all FLG loss-of-function mutation have biological equivalence on filaggrin protein 
expression, there is no clear biological plausibility for an interaction with one mutation and not another. 
Evidence for GEI comes from small numbers of individuals with FLG mutation, cat exposure and 
development of AD: in Bisgaard et al (N=5), Schuttelaar et al. did not provide the number but it can be 
inferred that N<84 for the overall interaction and N<50 for the 2282del4 interaction.22,23  
Dog exposure
Bisgaard et al  tested for an interaction between FLG loss-of-function mutations and dog ownership in the 
first year of life. There was no evidence for an interaction in COPSAC (n=379) (result statistics not 
reported) or MAAS (n=503) (HR=0.59, 95% CI:0.16-2.20, P=0.43).22 
Siblings
One study reported an interaction between FLG genotype and presence of older siblings amongst both 
children attending or not attending day-care at 2 years in two separate studies –LISAplus cohort (aged 6-
72 months, n=1037, interaction OR=3.27, 95% CI:1.14-9.36, P<0.05) and GINIplus cohort (12-72 months, 
n=1828, interaction OR=2.41, 95% CI:1.06-5.48, P<0.05).29 This interaction increased the risk of AD.30
Parity, maternal atopy and child’s sex 
Henderson et al found no evidence of an interaction between FLG genotype with parity 
(P=0.802)(n=4463), maternal asthma or AD (n=5188), (P=0.486 and P=0.884 respectively) or the child’s sex 
(P=0.959)24 in children aged 6 months to 11 years who were part of a prospective cohort study. 
Maternal IgE sensitisation
Esparza-Gordillo et al. conducted a parent-of-origin analysis investigating the effect of a child’s FLG 
genotype and maternal and paternal FLG genotypes on the child’s AD risk (n=1209 families). Although 
interactions were not the focus of this study, results were stratified by maternal IgE sensitization status, 
allowing us to compare the effect of child’s FLG genotype in those whose mothers were or were not IgE 
sensitized. The child’s FLG genotype had a stronger risk effect when mothers had normal IgE levels 
(Relative Risk for 1 FLG loss-of-function mutation=2.30 (95% CI:1.64-3.22); RR for 2 FLG loss-of-function 
mutations=7.19 (95%CI:3.77-13.7)) compared to those with sensitized mothers (RR1=1.37(95% CI:0.97-
1.94); RR2=2.98 (95 %CI:1.19-7.45)). However, confidence intervals were wide and overlapping. Esparza-A
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Gordillo et al. reported the opposite for effect of maternal genotype, so it is unclear if this evidence points 
to a true interaction with exposure to mothers with elevated IgE or whether the observation results from 
maternal genetic effects in utero or imprinting effects of FLG genotype.33
Smoking 
One study tested for possible interactions with FLG mutations and maternal smoking during pregnancy 
(n=5140) or childhood environmental tobacco smoke exposure (n=4874). Their results showed no 
evidence for either interaction (maternal smoking P=0.362, child environmental tobacco smoke exposure 
P=0.742).24
Breastfeeding
Ziyab et al. found evidence for a protective association between breastfeeding duration and AD in 
children aged 1 or 2 years old (n=885) carrying one or more FLG loss-of-function mutations (P=0.02), with 
no evidence in those without a FLG null mutation (P=0.64).25 However, this was stratified analysis and 
formal interaction testing was not undertaken. Henderson et al. found no evidence for this interaction 
(P=0.952) in their earlier, larger study (n=5158).24  
Birth year
Thyssen et al. investigated FLG and year of birth in adults aged 18-69 years (n=3202) but did not report 
any evidence of interaction (P=0.19) on AD risk.31 
Water hardness
Interaction of FLG genotype and water hardness has been investigated in two papers within the same 
cohort. Perkin et al. investigated calcium and chlorine levels in water and AD during the first three months 
of life in the Enquiring About Tolerance study, a UK population-based cohort of 1,303 infants. Interaction 
tests did not show a statistically significant interaction between FLG genotype and: high calcium-low 
chlorine concentration in water; low calcium-high chlorine;  or high calcium-high chlorine 
concentrations.29 They subsequently reported evidence of an interaction between FLG loss-of-function 
mutations and water hardness increasing AD risk, when studying high calcium (>256mg/L CaCO3) from 
three months of age in this cohort (n=1,303 total; n=75 with FLG null mutation exposed to high CaCO3 
levels, P=0.0008).37  
Vitamin DA
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A possible interaction between serum vitamin D levels and FLG genotype was investigated by Berents et 
al. They measured serum vitamin D levels in 558 participants at 1-13 months and 2 years alongside 
interviews assessing Vitamin D intake. They did not find any evidence for an interaction (P>0.13).32
Urine phthalate metabolites and household dust phthalate 
Phthalates are added to plastic to increase flexibility. They have been reported to be associated with 
childhood AD38. Wang et al. investigated whether there was an interaction between urine phthalate 
metabolite levels and FLG genotype in children aged 3 years in the aetiology of AD (n=453). They studied 
four phthalates, monoethyl phthalate (MEP), monobutyl phthalate (MBP), monobenzyl pthathlate (MBzP) 
and mono(2-ethyl-5-hydroxyhexyl)phthalate (5OHMEHP) which they classified as lower or higher levels in 
relation to the median. They reported evidence for an interaction between the P478S genotype TT and 
phthalates MBP (P=0.015) and MBzP (P=0.018)27 and increased AD risk; however, they did not replicate 
their findings or perform corrections for multiple testing.27 A similar interaction was investigated by Bamai 
et al. who assessed seven phthalates found in household dust, and eleven phosphorus flame retardants. 
They found evidence for an interaction between FLG loss-of-functions and diisononyl phthalate (DiNP) 
(P=0.039)26. The group also reported a non-significant negative dose-response relationship among 
children with FLG loss-of-function mutation(s) in a categorical model (first quartile compared with fourth 
quartile, P for trend = 0.087). This analysis was undertaken on a sample size of 5 children with AD and FLG 
null genotypes and the researchers did not correct for multiple testing.26 
Quality of studies
Most studies included unselected cases from the general population or cohorts, and controls were 
selected from the same population as those with AD. FLG genotype was assessed using accepted 
methodology (Supplementary table 3). The timing and method of assessment of environmental exposures 
was variable; studies may be vulnerable to reverse causality due to exposure status being assessed after 
AD onset. Participants in each study were of homogenous ethnicity and analyses were adjusted for age. 
Details of confounder adjustment was missing in five of 12 included studies (Supplementary Table 3). 
Studies varied in their presentation of interaction results, with some providing only a P value or statement 
of statistical significance and others also providing effect estimates and confidence intervals across strata 
and a P value for the interaction term or statement of statistical significance (Supplementary Table 2). 
None of the included studies adjusted for multiple testing and only Berents et al. reported power 
calculations.32 The results of the studies supported their conclusions, however they were underpowered - 
results of these studies must be interpreted with caution. Under reasonable assumptions on the A
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magnitude of main effects, prevalence of AD, environmental exposure and SNP allele frequency, post hoc 
power calculations (Supplementary Table 4) indicate that the sample size required to detect an 
interaction with OR ~2.0 is approximately 5,000 individuals, whereas a sample size of ~63,000 is required 
to detect a more modest GEI effect with OR 1.2. 
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Figure 1: Flow chart showing systematic review
43 full text articles excluded for 
the following reasons: 
12 were conference 
proceedings or abstract only 
10 had no interaction testing 
5 were duplicates not identified 
above
6 had an outcome that was not 
atopic dermatitis
2 did not have a control group 
2 comprised literature review 
2 were letters 
2 included no environmental 
factors 
1 presented no statistical 
analysis results
1 is follow on work informed by 
the preliminary findings of this 
systematic review   
1399 records identified 
through Embase via Ovid
1817 records screened by 
abstract 
55 full text articles assessed 
for eligibility 
1762 records excluded - title 
and/or abstract not on review 
topic
1526 records identified 
through BIOSIS 
750 records identified 
through Medline via Ovid
1858 duplicates removed 
12 papers included 
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Discussion 
Our results highlight important challenges when studying GEIs in the aetiology of AD. We identified only 
12 articles that reported FLG-environmental interactions in AD. Our initial search strategy returned many 
results, but the majority were excluded because they lacked information essential to the review. Evidence 
was found for interactions between FLG genotype and: breastfeeding duration, older siblings, phthalate 
exposure in household dust and urine phthalate metabolite levels, early-life exposure to cat and water 
hardness. All interactions increased the risk of AD apart from prolonged breastfeeding which decreased 
the risk. Because of very limited evidence to support these interactions, small numbers and lack of 
replication (one study undertook replication) it is difficult to interpret the results and findings must be 
interpreted with caution. Table 2 shows our suggestions of the components required for a rigorous GEI 
study which may improve conclusions from future studies. 
Table 2: Components required for rigorous GEI study
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Suggestion Reason 
Large sample size with mutation and 
environmental exposure (see supplementary 
table 4)
Sample size must be large enough to detect 
true GbyE interaction effect
Design the study basing the sample size on 
power to detect interaction effect
Design the study and basing the sample size on 
power to detect a main effect will likely result 
in insufficient sample size
Use accepted diagnostic criteria for AD  This reduces the possibility of introducing 
heterogeneity into the results 
Use robust methods of exposure measurement Questionnaires or indirect measurements of 
exposure can introduce variation and recall bias 
into the results. Using validated tools will help 
reproducibility and reduce information bias
Collect measurements of exposure at defined 
time periods across the study population
This avoids variation in the timing of exposure 
measurements influencing disease risk 
Correct for multiple testing and publication bias This reduces the possibility of interpreting 
chance results as positive findings 
Tailor studies to different ethnic groups 
currently not covered by research.
Increasing diversity in genetic research will 
enable us to understand the importance of GEI 
in populations of different ethnicities
Our review has several strengths. A detailed search strategy was used to identify all relevant papers.  
Screening and data extraction were carried out in duplicate, with secondary resolution of conflicts, 
reducing the possibility of introducing bias by systematically selecting certain papers. The majority (10/12, 
83%) of studies used data from cohort studies, thus they were able to consider temporality, and 
researchers mostly measured the outcome ‘AD’ using validated criteria.
Our findings should be considered in light of limitations. Many studies were excluded from the review as 
they did not specifically test for GEI in their analyses. Studies were also excluded if they measured indirect 
outcomes of AD by looking at IgE levels, transepidermal water loss, or skin-prick tests, which are not A
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measures of the outcome (AD), but responses to exposures. Many of the included studies  performed GEI 
analysis as a secondary analysis, for example, Berents et al.32 meaning they did not aim to have sufficient 
power to assess GEIs, hence, the importance of measuring GEIs as primary outcome (Table 2). We were 
unable to formally evaluate the risk of reporting biases, so cannot rule out the possibility that studies 
which found non-significant interactions yet failed to report such results are missing from our review. 
Many of the studies included in this review relied on population data and there may be heterogeneity in 
outcome definition (Table 2).39 The pre-defined scope of this review was to look at FLG-environmental 
interactions, which by definition has excluded the study of effects within populations where FLG null 
mutations are not prevalent or have not been identified. 7,40 Many large genetic studies have been within 
populations of European ancestry, where FLG null mutations are prevalent. On-going work to increase 
diversity in genetic research41 will allow future investigations of GEI in populations of all ethnicities (Table 
2). 
Heterogeneity in methodology between published studies and the limited number of studies assessing 
the same exposure precluded meta-analysis or formal assessment of publication bias. None of the 
included studies reported correcting for multiple testing; hence, interaction effects could be by chance. It 
is unclear how many studies had predefined hypotheses which risks introducing reporting bias. 
Replication of findings was limited and in some cases where two studies investigated the same 
interaction, discordant findings were seen, such as Ziyab et al. (FLG genotype and breastfeeding) and 
Henderson et al. 24,25 
One reason for the limited evidence for GEI and lack of replication is lack of statistical power. Detailed 
review showed the number of individuals on whom the interaction analysis was based (i.e. cases with 
both exposure and FLG-null genotype) was small, hence, included studies were likely to be 
underpowered. The number of individuals with both a FLG loss-of-function mutation and exposure to the 
specific environmental factor was not always specified, but of those that did, it ranged from N=5 to 
N=167.22,24 
In complex diseases such as AD, where the main genetic effect sizes are small, a large sample size is 
necessary to detect small interaction effects.42 Researchers need to utilise sufficiently large sample sizes 
to detect GEIs, and generally investigators should demonstrate that their sample has adequate power to 
detect an interaction effect.43 Even in cases where meta-analysis across studies is possible, results are not 
always meaningful due to variable measurement of environmental exposures.42 
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Studies of GEI face inherent challenges in attempting to gain full understanding of interactions because of 
the difficulty in uniformly measuring the environmental parameter, which in turn limits the understanding 
of the underlying disease mechanism.44 The difficulty in measuring exposure in GEI studies in AD is shown 
in the Wang et al. study that tested for an interaction between phthalate exposure and FLG genotype. To 
measure exposure, phthalate metabolite levels were measured from urine samples.27 This is not a direct 
measure of the exposure, therefore we questioned whether it should be included in the review. It only 
provides a moderate prediction of exposure due to the short half-life and rapid excretion of phthalates 
leading to considerable day-to-day variation.27 Other studies used different methods, such as 
questionnaires, to derive environmental exposure data retrospectively; this could introduce recall bias.30
Variation in the timing of environmental exposure is important in terms of influencing subsequent disease 
risk, as timing of exposure may not be accurately measured with methods such as infrequent 
questionnaires.45 Using robust validated measures of exposure reduces variation and aids reproducibility 
of results (Table 2). For some of these exposures it is easy to hypothesise a biological explanation as to 
why people with FLG haploinsufficiency might have different responses for example; pet exposure and 
older siblings could act via microbial exposure, as proposed by the hygiene hypothesis.46 With other 
possible interactions such as urine phthalate metabolites, it is harder to hypothesise plausible 
mechanisms. Cohort studies may be vulnerable to reverse causality when assessing early life exposures, 
as, although outcomes were measured after the exposure in the majority of studies, there remains a 
possibility that early signs of AD, or the presence of older siblings with AD, influenced the behaviour of 
parents who subsequently modified the exposure. 
GEI are widely viewed as important in the aetiology of AD. However, the limited evidence and lack of 
power of published studies to detect GEI effects as indicated by the sample size calculations we carried 
out highlights the importance of further research.  This is needed to test for replication of interactions 
reported to date (Table 1) using larger sample sizes.  Further, unexplored GEI may also warrant 
investigation, including genetic risk variants in addition to FLG loss-of-function mutations. The Early 
Genetics and Lifecourse Epidemiology (EAGLE) consortium is investigating possible GEIs with selected 
SNPs associated with AD. Our recommendations for future studies of GbyE can be shown in Table 2 which 
would improve the quality of evidence and enable us to draw more robust conclusions about the nature 
of GEIs. Together this work will improve understanding of GEI in the aetiology of AD, to inform both public 
health and individual lifestyle decisions.
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